Transforming Alzheimer’s Treatment: Innovative Combinations to Boost Cognition
NetworkNewsWire Editorial Coverage New York, NY – October 1, 2024 – Alzheimer’s disease (AD) has become a focal point in the pharmaceutical industry as recent drugs such as Leqembi and Kisunla have received U.S. Food and Drug Administration (FDA) approval. However, while these treatments may slow cognitive decline in AD patients, they do not […]
As Fentanyl Crisis Escalates, Abuse-Deterrent Formulations to Zero in on the Rising Epidemic of Opiate Abuse
Palm Beach, FL – September 24, 2024 – Abuse-deterrent transdermal technology can be used to prevent the misuse of drugs with abuse potential, such as fentanyl, by incorporating aversive agents into transdermal patches. Abuse-deterrent opioid formulations (ADFs) are designed to make it more difficult to abuse opioids by making them less attractive or rewarding, or […]
How Critical Demand for Metastatic Breast Cancer Therapies is Producing a Multi-Billion Dollar Opportunity for Biotechs
Palm Beach, FL – September 20, 2024 – Breast cancer is an illness in which the breast cells get uncontrollably large. The type of breast cancer depends on which cells in the breast become cancerous. Cancer cells removed during the biopsy are examined to check the presence of progesterone or estrogen receptor proteins. The hormones, […]
Treatment AI Passes Medical School Clinical Exam with 92% Success Rate
VANCOUVER, British Columbia, March 20, 2024 – Treatment.com AI Inc. (OTCQB: TREIF) (CSE: TRUE) (Frankfurt: 939) (the “Company” or “Treatment”) is pleased to announce that it’s AI medical information support platform was used in the “Objective Structured Clinical Examination” (“OSCE”), a standard clinical exam of diagnostic aptitude at medical and nursing schools, passing the exam […]
PANGEA ANNOUNCES PRODUCT LISTING INTO URBAN FARE, WESTERN CANADA’S GOURMET SUPERMARKET CHAIN
Vancouver, British Columbia, September 22, 2022 – Pangea Natural Foods Inc. (CSE: PNGA) (“Pangea” or the “Company”), a natural food company, is pleased to announce the listing of its Old Fashioned Ghee in all Urban Fare stores located across multiple upscale districts in British Columbia and Alberta. Urban Fare is a subsidiary of the […]
PANGEA ANNOUNCES NEW MUNCHIE MIX AND DISTRIBUTION WITH AIR CANADA
VANCOUVER, BC , Sept. 7, 2022 /CNW/ – Pangea Natural Foods Inc. (CSE: PNGA) (” Pangea ” or the ” Company “), a natural food company, is pleased to announce the launch of Pangea Munchie Mix, a high-protein snack mix which will be available on Air Canada’s network of flights. The Company’s Munchie Mix is a superfood rich snack made with dried cranberries, […]
3 Marijuana Stocks That Have Made Recent Headlines
USA NEWS GROUP MARKET COMMENTARY Vancouver, BC – April 16, 2021 – USA News Group – The marijuana industry is a budding sector that is increasing rapidly as more companies become public in the U.S. and Canada, but some of them are overvalued and can be attractive to short sellers. While investors are drawn […]
Recent Earning Reports for Mobile Gaming Stocks Showing Healthy, Steady Growth
Palm Beach, FL – August 10, 2020 – The global health pandemic has had an incredibly negative impact on most businesses and markets across the globe, but there are actually some markets that have thriving because of the pandemic. The global gaming market is one of those exceptions. Revenues are booming in this industry this […]
QMC Irgon Lithium Mine Project Update
Vancouver, BC – April 21, 2020 – QMC Quantum Minerals Corp., (TSXV: QMC) (FSE: 3LQ) (OTC Pink: QMCQF) (“QMC” or “the Company”) is pleased to provide a corporate update. The Company has had recent discussions with Sinomine Group Co., Ltd. (“Sinomine”) to process spodumene material from the Irgon Lithium Mine Property at the TANCO plant. The […]
Hoth Therapeutics Commences Next Phase of VNLG-152 Study
Solubility and formulation had been established for the drug in the treatment of dermatological diseases New York, NY- April 09, 2020 – Hoth Therapeutics, Inc. (NASDAQ: HOTH), a biopharmaceutical company, today announced initiating the next phase of its study of VNLG-152, a Novel retinamides (Retinoic acid metabolism blocking agents or RAMBAs) for the treatment of dermatological diseases, […]
